Intervention not reported
PUFA(2 trials; 95 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Vitamin E(1 trial; 167 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Prebiotics/Probiotics/Synbiotics(6 trials; 296 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Prebiotics/Probiotics/Synbiotics(5 trials; 289 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
PUFA(9 trials; 750 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Vitamin E(4 trials; 379 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Other antioxidants(3 trials; 191 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Vitamin D(4 trials; 241 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Amino acids(2 trials; 158 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Cognitive function · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Cognitive function · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Functional ability: independence with activities of daily living at discharge from hospital · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Adverse events (all adverse events) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments
It is very uncertain whether rivastigmine changes adverse events (all adverse events) at 24 to 26 weeks compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments
Rivastigmine showed no clear difference in serious adverse events (excluding death) at 24 to 26 weeks compared with placebo (low certainty).
1 finding from 1 review
Cognitive function · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale · vascular dementia and other vascular cognitive impairments
Galantamine leads to higher clinical global impression: CIBIC‐Plus (Improvement) at 26 weeks compared with placebo (high certainty).
1 finding from 1 review
Functional performance and activities of daily living at 26 weeks ADCS‐ADL and DAD · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Adverse events (all adverse events) at 26 weeks · vascular dementia and other vascular cognitive impairments
Galantamine probably leads to higher adverse events (all adverse events) at 26 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (excluding deaths) at 26 weeks · vascular dementia and other vascular cognitive impairments
Galantamine showed no clear difference in serious adverse events (excluding deaths) at 26 weeks compared with placebo (moderate certainty).
1 finding from 1 review